 Wall Street Journal |
Bristol Puts Focus on Diabetes Treatment
Wall Street Journal Bristol-Myers Squibb hopes to accelerate sales of diabetes drug Bydureon, which Bristol stands to obtain with its proposed purchase of Amylin. Diabetes Treatment: Bristol-Myers Buys Amylin PharmaceuticalsWebProNews TEXT-Fitch cuts Bristol-Myers Squibb ratingsReuters Ahead of the Bell: Amylin Pharma shares climbBusinessweek Worcester Telegram all 443 news articles » |
More details can be found at www.diabeteshowto.com
Discussion
Comments are disallowed for this post.
Comments are closed.